Sources

4 Total Sources

Skyhawk Reports 69% Huntingtin Reduction for SKY-0515 as 12-Month HD Data Support Phase 2/3 Push

en.hdbuzz.net1d ago

Skyhawk's SKY-0515 Shows 69% Huntingtin Reduction, Encouraging Clinical Trends in 12-Month Phase 1/2 Data

recnews.it1d ago

Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - Rec News

weeklyvoice.com1d ago

Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease – Weekly Voice

hda.org.uk1d ago

Huntington's Disease Association - Improvement in Huntington's disease patients in Skyhawk Therapeutics trial